AbbVie Inc (ABBV)vsCVS Health Corp (CVS)
ABBV
AbbVie Inc
$288.85
-2.05%
HEALTHCARE · Cap: $521.11B
CVS
CVS Health Corp
$90.25
-0.09%
HEALTHCARE · Cap: $115.43B
Smart Verdict
WallStSmart Research — data-driven comparison
CVS Health Corp generates 525% more annual revenue ($412.64B vs $66.01B). ABBV leads profitability with a 15.7% profit margin vs 1.2%. CVS appears more attractively valued with a PEG of 0.21. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
CVS
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.85
$132.01 premium
Margin of Safety
+44.9%
Fair Value
$139.84
Current Price
$90.25
$49.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 188.8% YoY
Large-cap with strong market position
Generating 5.7B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
ROE of 6.2% — below average capital efficiency
1.2% margin — thin
Operating margin of 3.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : CVS
The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.21 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : CVS
The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a mature stock while CVS is a value play — different risk/reward profiles.
CVS carries more volatility with a beta of 0.60 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
CVS generates stronger free cash flow (5.7B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 67/100), backed by strong 15.7% margins and 10.3% revenue growth. CVS offers better value entry with a 44.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CVS Health Corp
HEALTHCARE · HEALTHCARE PLANS · USA
CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?